Cytek Biosciences, Inc.
About Cytek Biosciences, Inc.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $201.5M
- Net income
- -$66.5M
- Total assets
- $461.5M
- Market cap
- $528.2M
- Gross margin
- 51.8%
- Operating margin
- -20.0%
- Net margin
- -33.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $201.5M
- Cost of revenue
- $97.0M
- Gross profit
- $104.5M
- Operating expenses
- $144.8M
- Operating income
- -$40.4M
- Income tax
- $36.7M
- Net income
- -$66.5M
Balance sheet
- Total assets
- $461.5M
- Current assets
- $392.0M
- Total liabilities
- $119.8M
- Current liabilities
- $77.8M
- Shareholders’ equity
- $341.7M
Cash flow
- Operating cash flow
- -$4.7M
- Investing cash flow
- $10.1M
- Financing cash flow
- -$13.4M
- Net cash flow
- -$7.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $528.2M
- Shares outstanding
- 130.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 23, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $66.5M in FY2025.
- Revenue grew 57% from FY2021 to FY2025.
- Gross margin of 51.8%, net margin -33.0%.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cytek Biosciences, Inc..
Write a review
News about Cytek Biosciences, Inc.
News & sentiment via Polygon.io
